首页 | 本学科首页   官方微博 | 高级检索  
检索        

柳氮磺胺吡啶联合微生态制剂治疗溃疡性结肠炎的临床研究
引用本文:余雷,易星航.柳氮磺胺吡啶联合微生态制剂治疗溃疡性结肠炎的临床研究[J].海南医学院学报,2014(8):1076-1078.
作者姓名:余雷  易星航
作者单位:重庆市九龙坡区第一人民医院内科,重庆400000
基金项目:中国高校医学期刊临床专项资金项目(11221665)
摘    要:目的:探讨柳氮磺胺吡啶(SASP)联合常美安等微生态制剂治疗溃疡性结肠炎的疗效优势。方法:选择经内镜确诊为溃疡性结肠炎(UC)的患者84例,随机分为对照组(n=42例,单用SASP口服治疗,剂量为1.0g,每日4次)和实验组(n=42例,在口服SASP治疗基础上联用微生态制剂常美安,2粒/次,3次/d),治疗14周后,比较两组Sutherland疾病活动性指数变化情况;采用免疫组化法检测其肠粘膜局部白介素-10(IL-10),白介素-6(IL-6)、白介素-18(IL-18)等细胞因子的变化;主观评价临床疗效、镜下以及组织学病变改善情况。结果:两组治疗前Sutherland指数比较,差异无统计学意义(P〉0.05);但经14周治疗后,实验组的Sutherland指数低于对照组,IL-10水平升高以及IL-6、IL-18水平降低幅度均优于对照组,差异具有统计学意义(P〈0.05);两组在主观评价临床疗效、镜下以及组织学等3方面的病变改善情况比较,差异具有统计学意义(P〈0.05)。结论:SASP联合微生态制剂治疗UC的临床效果明显优于单用SASP,且其不良反应少,安全性高,值得临床推广。

关 键 词:微生态制剂  Sutherland指数  柳氮磺胺吡啶  溃疡性结肠炎

Clinical research of Sulfasalazine combined probiotics in the treatment of ulcerative colitis
YU Lei,YI Xing-hang.Clinical research of Sulfasalazine combined probiotics in the treatment of ulcerative colitis[J].Journal of Hainan Medical College,2014(8):1076-1078.
Authors:YU Lei  YI Xing-hang
Institution:(Department of Internal Medicine, The First People's Hospital of Jiulongpo District, Chongqing 400000,China)
Abstract:Objective: To investigate the value of sulfasalazine (SASP) combing with probiotics on ulcerative colitis. Methods: A total of 84 patients with confirmed ulcerative colitis were randomly assigned into control group and treatment group, the control group (n=42 cases) was given oral dose of SASP (1.0 g, 4 times a day ) and observation group (n=42 cases) was given oral SASP therapy and prohiotics America (2/each, three times a day). After 14 weeks of treatment, changes in Sutherland disease Activity Index. Changes in local interleukin -10 (IL-10) of intestinal mucosa, interleukin -6 (IL-6), interleukin-18 (IL-18) cytokines were detected with immunohistochemistry method, subjective evaluation of clinical efficacy, improvements in histological lesions under endoscopy were compared between the two groups. Results: Before treatment, no significant difference in Sutherland index was observed (P〈0.05). After 14 weeks of treatment, the Sutherland index of observation group was significant lower than the control group (P〈0.05). Improvements in IL-10 (increased), IL-6 and IL-18 (decreased) were superior in observation group than that in control group. Significant differences in subjective evaluation of clinical efficacy, endoscopic and histological lesions were observed (P〈0.05). Conclusion: SASP combining with probiotics America show superior effects on UC comparing with SASP treatment alone without inducing more adverse reactions, thus it's worthy of application in large scale.
Keywords:Probiotics  Sutherland index  Sulfasalazine  Ulcerative colitis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号